Cartesian Therapeutics (RNAC) Debt Ratio (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Debt Ratio for 9 consecutive years, with 0.17 the latest figure, recorded in Q2 2023.

• In Q2 2023, Debt Ratio rose 24.94% year-over-year to 0.17; the TTM figure through Jun 2023 stood at 0.17 (up 24.94% YoY), while the FY2022 annual figure was 0.16, down 1.26% from the prior year.
• Debt Ratio rose to 0.17 in Q2 2023 per RNAC's latest filing, from 0.17 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.53 in Q3 2019 and bottomed at 0.14 in Q3 2020.
• Historically, Debt Ratio has averaged 0.21 across 5 years, with a median of 0.17 in 2021.
• Annual changes were most pronounced in 2019 — Debt Ratio soared 58.9% — and 2020, when it sank 74.33%.
• Cartesian Therapeutics' Debt Ratio stood at 0.19 in 2019, then dropped by 21.07% to 0.15 in 2020, then grew by 6.98% to 0.16 in 2021, then retreated by 1.26% to 0.16 in 2022, then gained by 8.77% to 0.17 in 2023.
• Business Quant data shows RNAC's Debt Ratio at 0.17 in Q2 2023, 0.17 in Q1 2023, and 0.16 in Q4 2022.